43例寡转移NSCLC立体定向放疗结果分析

目的 探讨应用立体定向放疗技术对寡转移NSCLC患者胸内原发灶及所有转移灶行根治性放疗的疗效和不良反应。方法 回顾分析2009—2015年间我科初治转移灶≤5个的NSCLC患者43例,采用立体定向放疗技术,对其原发灶及所有转移灶均行根治性放疗,平均和中位BED₁₀分别为101.416 Gy和102.700 Gy,中位化疗周期数4个。采用Kaplan-Meier法生存分析,Cox模型多因素预后分析。结果 中位随访时间36个月,病灶治疗总有效率为86%,1、2、3年OS分别为74%、70%、51%,中位OS时间为48个月,中位PFS时间为15个月。多因素分析结果提示ECOG<2与ECOG≥2(P=0.000)、BED₁₀<100 Gy与≥100 Gy (P=0.006)对生存预后有显著影响。约90%患者仅出1—2级不良反应,未出现治疗相关性死亡。结论 寡转移NSCLC在接受系统性全身治疗前提下联合原发灶和转移灶根治性放疗可显著改善患者OS和PFS,不良反应可耐受。

Result of stereotactic radiotherapy of oligometastasis non-small cell lung cancer

Objective To explore the curative effect and adverse reaction of applying stereotactic radiotherapy to primary lesion inside chest cavity of patients with oligometastasis non-small cell lung cancer and rendering radical radiotherapy to all metastases. Methods 43 patients with≤5 metastases of non-small cell lung cancer received initial treatment during 2009-2015 in our department were analyzed;the stereotactic radiotherapy was adopted to implement radical radiotherapy on primary lesion and all metastases. The average and neutral position BED10 respectively were 101416 Gy and 102700 Gy,the number of neutral position chemotherapy period was 4. Kaplan-Meier method, survival analysis, Cox model, multi factor Prognosis analysis were used. Results By the end of January 10,2017 in 36 months' neutral position follow-up visit, the total effective rate of lesion treatment of 86%;the survival rates after 1,2 and 3 years respectively were 74%, 70% and 51%. Neutral survival time was 48 months, and the progression-free time of neutral position was 15 months. Multi-factor analysis indicated that,ECOG<2 and ECOG≥2(P=0000),BED10<100 Gy and BED10≥100 Gy ( P=0006) generated obvious influence on survival prognosis. About 90% of the patients only got 1-2 degree of adverse reaction without emerging treatment related death. Conclusions On the premise of systematic therapy of oligometastasis non-small cell lung cancer, combined with radical radiotherapy of primary lesion and metastasis can obviously improve patients ' overall survival and progression-free survival,the adverse reaction is durable.